These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38912501)
1. Assessing the efficacy of Alpha Pierce LR Heliyon; 2024 Jun; 10(11):e31183. PubMed ID: 38912501 [TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Rahaghi FF; Miravitlles M Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837 [TBL] [Abstract][Full Text] [Related]
3. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857 [TBL] [Abstract][Full Text] [Related]
4. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. Tortorici MA; Rogers JA; Vit O; Bexon M; Sandhaus RA; Burdon J; Chorostowska-Wynimko J; Thompson P; Stocks J; McElvaney NG; Chapman KR; Edelman JM Br J Clin Pharmacol; 2017 Nov; 83(11):2386-2397. PubMed ID: 28662542 [TBL] [Abstract][Full Text] [Related]
5. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG; Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936 [TBL] [Abstract][Full Text] [Related]
6. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314 [TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647 [TBL] [Abstract][Full Text] [Related]
8. Comparison among populations with severe and intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease. Piloni D; Ottaviani S; Saderi L; Corda L; Baderna P; Barzon V; Balderacchi AM; Seebacher C; Balbi B; Albicini F; Corino A; Mennitti MC; Tirelli C; Spreafico F; Bosio M; Mariani F; Sotgiu G; Corsico AG; Ferrarotti I Minerva Med; 2024 Feb; 115(1):23-31. PubMed ID: 37021471 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Petrache I; Hajjar J; Campos M Biologics; 2009; 3():193-204. PubMed ID: 19707408 [TBL] [Abstract][Full Text] [Related]
10. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Sclar DA; Evans MA; Robison LM; Skaer TL Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280 [TBL] [Abstract][Full Text] [Related]
11. Alpha1-antitrypsin deficiency: a clinical-genetic overview. Abboud RT; Nelson TN; Jung B; Mattman A Appl Clin Genet; 2011; 4():55-65. PubMed ID: 23776367 [TBL] [Abstract][Full Text] [Related]